Combination checkpoint therapy with anti-PD-1 and anti-BTLA results in a synergistic therapeutic effect against murine glioblastoma

Clinical trials involving anti-programmed cell death protein-1 (anti-PD-1) failed to demonstrate improved overall survival in glioblastoma (GBM) patients. This may be due to the expression of alternative checkpoints such as B- and T- lymphocyte attenuator (BTLA) on several immune cell types includin...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, John, Medikonda, Ravi, Saleh, Laura, Kim, Timothy, Pant, Ayush, Srivastava, Siddhartha, Kim, Young-Hoon, Jackson, Christina, Tong, Luqing, Routkevitch, Denis, Jackson, Christopher, Mathios, Dimitrios, Zhao, Tianna, Cho, Hyerim, Brem, Henry, Lim, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409779/
https://www.ncbi.nlm.nih.gov/pubmed/34484870
http://dx.doi.org/10.1080/2162402X.2021.1956142

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409779/
https://www.ncbi.nlm.nih.gov/pubmed/34484870
http://dx.doi.org/10.1080/2162402X.2021.1956142

Ejemplares similares